Stryker

SYK on NYSE. Stryker sells medical devices and surgical equipment to hospitals and surgeons. Market value $109.4bn.

Watch this stockFree. We tell you when something changes.

Price checks use the past 12 months to June 2026. Quality checks use five annual reports, the latest for the year to December 2025.

Should I look at this?

Good business, but not cheap right now

See cheaper Health care stocks on the list

This is not advice. Check the numbers below.

Compare with another stock

Cash yield
past 12 months to June 2026
4.4%fair

For every $100 of what the whole company costs, it produced $4.41 of spare cash in the past 12 months. A savings account pays about $4.

Price to profit
past 12 months to June 2026
21.4×full

You pay 21.4 years of operating profit for the business. The average large US company costs around 18.

Return on capital
five annual reports to December 2025
9.5%five-year median

Each dollar kept in the business earns 10 cents a year. Above 10 is good.

Quality score: 92 of 100. Price score: 59 of 100. Our list needs 70 on quality and 60 on price.

$278.20 a share, 4% above its 1-year low

Over the past year the price has ranged from $267.00 to $392.55.

Dividend: 1.2% a year

Paid every year for at least 5 years

Prices from Tuesday’s close (6 October).

Five years of cash, in billions

2.7
2.0
3.1
3.5
4.3
4.7
2021202220232024202512 monthsto Jun '26
Revenue
$17.1bn$18.4bn$20.5bn$22.6bn$25.1bn
Operating margin
15.1%15.4%19.0%16.3%19.5%
Debt to equity
0.840.790.700.660.71
Shares outstanding
0.38bn0.38bn0.38bn0.38bn0.38bn

Health checks

  • Free cash flow positive5 of 5 years
  • Accounting looks honest (Beneish)Nothing unusual
  • Financial strength (Piotroski)5 of 8 checks we could run
  • Profit backed by cash (accruals)Yes
  • Debt0.71× equity
  • Revenue growth, five yearsStrong, 11.8% a year
  • Buying back its own sharesRoughly flat

The quarter to June 2026

How the business did, compared with the same quarter a year earlier.

  • Sales: $6.6 billion last quarter, up 9% on a year ago.
  • Profit: $1.3 billion, up 44% on a year ago.
  • It keeps 21 cents of each $1 of sales as operating profit, up from 15 cents a year earlier.
  • Spare cash over the past 12 months: $4.7 billion, up from $4 billion.
  • About the same number of shares as a year ago.
  • Debt is $11.6 billion more than cash, down from $14.2 billion a year ago.
  • Sales grew on a year ago in each of the last 4 quarters.
Sales by quarter
Sales by quarter
Quarter toAmount
September 2024$5.5bn
December 2024$6.4bn
March 2025$5.9bn
June 2025$6.0bn
September 2025$6.1bn
December 2025$7.2bn
March 2026$6.0bn
June 2026$6.6bn
Profit by quarter
Profit by quarter
Quarter toAmount
September 2024$834m
December 2024$546m
March 2025$654m
June 2025$884m
September 2025$859m
December 2025$849m
March 2026$745m
June 2026$1.3bn

From the company's quarterly reports to the SEC.

Dates

Next results (estimated)
29 October 2026
Last annual report (10-K)
11 February 2026
Next quarterly (estimated, 10-Q)
30 October 2026

Who owns it

11 long-term investors we follow own it, up from 10 last quarter. 2,257 funds in all.

Jun '25
Dec '25
Jun '26
Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

1 investor owns more than 5%.

  • 6.7%
    Since 31 March 2026
  • GREENLEAF TRUST
    Passive investor
    Sold down below 5%
    Since 31 December 2025
  • STRYKER RONDA E
    Sold down below 5%
    Since 27 February 2026
    What they said

    Ronda E. Stryker intends to evaluate on an ongoing basis her investment in the Company and her options with respect to such investment. Ronda E. Stryker and her husband may, from time to time, acquire additional Common Shares (1) by the exercise or additional vesting of options,…

    Read the filing
  • The Vanguard Group
    Passive investor
    Sold down below 5%
    Since 13 March 2026

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

No insider bought shares on the open market in the last 12 months. 8 sold $586m, $1m of it under preset trading plans.

  • Crotty Dylan Bram
    Group President
    Sold
    Date
    21 August 2026
    Shares
    441
    Price
    $328.61
    Value
    $144,915
  • STRYKER RONDA E
    Director
    Sold
    Date
    19 August 2026
    Shares
    50,000
    Price
    $340.10
    Value
    $17m
  • STRYKER RONDA E
    Director
    Sold
    Date
    18 August 2026
    Shares
    300,000
    Price
    $335.90
    Value
    $101m
  • King Debra
    See Remarks
    Sold
    Date
    18 August 2026
    Shares
    826
    Price
    $336.30
    Value
    $277,787
  • Fletcher Robert S
    VP, Chief Legal Officer
    Sold
    under a preset trading plan
    Date
    28 May 2026
    Shares
    4,544
    Price
    $306.87
    Value
    $1m
  • STRYKER RONDA E
    Director
    Sold
    Date
    26 May 2026
    Shares
    310,000
    Price
    $312.23
    Value
    $97m
  • Fink M Kathryn
    VP, Chief HR Officer
    Sold
    Date
    11 May 2026
    Shares
    8,720
    Price
    $283.69
    Value
    $2m
  • STRYKER RONDA E
    Director
    Sold
    Date
    5 February 2026
    Shares
    250,000
    Price
    $363.96
    Value
    $91m
  • STRYKER RONDA E
    Director
    Sold
    Date
    4 February 2026
    Shares
    250,000
    Price
    $362.92
    Value
    $91m
  • Pierce James Andrew
    Group President
    Sold
    Date
    2 February 2026
    Shares
    475
    Price
    $368.87
    Value
    $175,213

From Form 4 filings: insiders must report trades in their own company's shares within two days.

What could go wrong

Cheap for a reason is the question the numbers cannot answer.

Whether the price already reflects the risks is what the deep dive is for.

What changed in the risks this year

Companies must list what could hurt them each year. These are the parts that changed since last year’s report.

  • allocation of income to each of the income tax jurisdictions

    Could happen
    Income tax audits associated with the allocation of income and other complex issues, including inventory transfer pricing and cost sharing, product royalty and foreign branch arrangements, may require an extended period to resolve and may result in significant income tax adjustments including the assessment of additional income taxes, interest and penalties. For example, we received a final audit report and assessments from the German Federal Central Tax Office ("FCTO") related to audits of tax years 2010 through 2017. Although we intend to defend our filing positions through the FCTO independent appeals process and, if necessary, litigation, there can be no assurance that we will be successful. If the resolution of this matter results in additional German income taxes, we intend to seek associated foreign tax credits, but such credits may not be available on a timely basis or at all, or may not fully offset any additional liability. Any such outcome could materially adversely affect our business, financial condition and results of operations. See Note 11 to our Consolidated Financial Statements for more information.
    Read more

Read it in the annual report

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from

It's near its lowest price in a year. The deep dive tells you if that's a bargain or a warning.

Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.